Variables | Outcomes |
---|---|
Age (mean ± SD) (years) (range) | 68.59 ± 9.74 (61–87) |
Gender (n) (%) | |
Male | 8 (36.4%) |
Female | 14 (63.6%) |
BMI (mean ± SD) (range) | 24.66 ± 3.52; 21–30 |
Smoking history | 9 (40.9%) |
Bone qualitya | |
Normal | 2 (9.1%) |
Osteopenia | 3 (13.6%) |
Osteoporosis | 17 (77.3%) |
Chronic comorbidity (n) (%) | |
Hypertension | 6 (27.3%) |
diabetes mellitus | 4 (18.2%) |
cerebral infarction | 2 (9.1%) |
cardiac insufficiency | 3 (13.6%) |
COPD | 1 (4.5%) |
Asthma | 1 (4.5%) |
Fractured segment (n) (%) | |
L3 | 4 (18.2%) |
L4 | 6 (27.3%) |
L5 | 12 (54.5%) |
Type of fracture (n) (%) | |
A1 | 15 (68.2%) |
A2 | 3 (13.6%) |
A3 | 4 (18.2%) |
Fracture characteristicsb(n) (%) | |
SEP | 6 (27.3%) |
IEP | 11 (50.0%) |
SEP + IEP | 5 (22.7%) |
canal encroachment | 4 (18.2%) |
Kummel disease | 2 (9.1%) |
Preexisting degeneration (n) (%) | |
LDH | 2 (9.1%) |
foraminal stenosis | 7 (31.8%) |
canal stenosis | 3 (13.6%) |
Total | 12 (54.5%) |
Anti-osteoporotic therapy (n) (%) | |
Denosumab | 15 (68.2%) |
Zoledronic Acid | 7 (31.8%) |
Duration (mean ± SD) (month) | 14.96 ± 2.33 |